-- 根据德国联邦统计局周三公布的初步数据，德国4月份年通胀率从3月份的2.7%升至2.9%。 最新数据显示，通胀率低于市场普遍预期的3%。 4月份消费者价格指数环比上涨0.6%，低于前值1.1%和市场预期的0.7%。 4月份调和通胀率为2.9%，低于前值2.8%和市场预期的3.1%。同时，4月份调和消费者价格指数环比上涨0.5%，低于前值1.2%和市场预期的0.8%。
Related Articles
Australia
Ryde Signs MoU With VinaTaxi to Explore Vietnam Opportunities
Ryde Group (RYDE) said Wednesday that it has signed a memorandum of understanding with VinaTaxi to explore strategic collaboration opportunities in Vietnam.The areas of exploration include the deployment of Ryde's platform within VinaTaxi's taxi fleet, and the development of an electric motorcycle ride-hailing ecosystem, the company said.Price: $1.20, Change: $+0.02, Percent Change: +1.61%
$RYDE
Research
Research Alert: Biogen Q1 Earnings: Strong Beat Overshadowed By Lowered Full-year Eps Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Biogen delivered strong Q1 2026 results with non-GAAP EPS of $3.57 (+18% Y/Y) significantly exceeding the consensus of $2.95, while revenue of $2.478B (+2% Y/Y) beat expectations of $2.2B. Growth products sustained impressive momentum, generating $851M (+12% Y/Y), now representing one-third of total revenue, with LEQEMBI collaboration revenue up 80% Y/Y to $60M and the MS franchise showing better-than-expected resilience at $779M (-4% Y/Y). We view the continued acceleration of growth products as demonstrating successful portfolio diversification away from MS dependence. Management downgraded 2026 non-GAAP EPS guidance to $14.25-$15.25 from $15.25-$16.25, primarily reflecting acquired IPR&D charges. The proposed $5.6B Apellis acquisition, expected to close in Q2 2026, will add SYFOVRE and EMPAVELI to the growth portfolio and is anticipated to be accretive in 2027, in our view. We expect the combined revenue from these assets to grow in the mid-to-high teens for at least the next two years.
$BIIB
Australia
Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program
Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.Price: $8.17, Change: $-0.07, Percent Change: -0.79%
$EBS$SABS